Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
References (24)
- et al.
Effect of ammonium ions on synaptic transmission in the mammalian central nervous system
Prog Neurobiol
(1992) - et al.
Ammonia potentiates GABAA response in dissociated rat cortical neurons
Neurosci Lett
(1993) - et al.
Modulation of ligand binding to components of the GABAA receptor complex by ammonia: implications for the pathogenesis of hyperammonemic syndromes
Brain Res
(1996) - et al.
Manganese and chronic hepatic encephalopathy
Lancet
(1995) - et al.
Effects of ornithine aspartate on plasma ammmonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design
J Hepatol
(1993) - et al.
Hepatocyte heterogeneity in ammonia metabolism: impairment of glutamine synthetase in CCl4-induced liver cell necrosis with no effect on urea synthesis
Chem Biol Interact
(1984) Hepatic encephalopathy and brain edema in acute hepatic failure. Does glutamate play a role?
Hepatology
(1997)Synaptic transmission in ammonia intoxication
Neurochem Pathol
(1987)Hepatic encephalopathy
- et al.
Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats
Hepatology
(1997)
The theoretic therapy of hepatic encephalopathy
Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
Hepatology
Cited by (144)
Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials
2024, Arab Journal of GastroenterologyEndogenous Metabolic Modulators: Emerging Therapeutic Potential of Amino Acids
2020, iScienceCitation Excerpt :LOLA promotes urea synthesis and reduces blood ammonia, a key toxin in HE pathogenesis (Gebhardt et al., 1997; Kircheis and Luth, 2019). LOLA has potential as a treatment for overt and minimal HE (Alvares-Da-Silva et al., 2014; Kircheis et al., 1997; Sharma et al., 2014; Stauch et al., 1998). In a double-blind randomized trial, LOLA (six months) versus placebo significantly improved secondary HE prophylaxis among patients with cirrhosis (n = 73) (Varakanahalli et al., 2018).
Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis
2020, Clinical Gastroenterology and HepatologyL-Ornithine L-Aspartate is Effective and Safe for the Treatment of Hepatic Encephalopathy in Cirrhosis
2018, Journal of Clinical and Experimental HepatologyEfficacy of L-Ornithine L-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
2018, Journal of Clinical and Experimental HepatologyNeuropsychiatric performance in patients with cirrhosis: Who is “normal”?
2017, Journal of HepatologyCitation Excerpt :Thus, in many ways, the definition of normal neuropsychiatric performance has been largely dependent on the definition of minimal HE (and thus its absence) and on the availability and the features of pertinent, local normative data. A summary of the definitions of minimal HE and/or normal neuropsychiatric performance in a set of relevant studies published between 1989 and 2016 is presented in Supplementary Table 1 [8,9,27–61]. While this literature review does not aim at being comprehensive, it provides a snapshot of the variability of definitions utilised over a period of approximately 30 years.